PLSE NASDAQ
Credit Risk of going bust: lower than 73% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down more than 99.9%), Pulse Biosciences, Inc. would be worth roughly what it owes.
Total debt $6.8M against a stock market value of $3.76B.
Distance to default 8.19 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 82.1%; Altman Z 132.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Miami, FL 33131
US
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Teplitsky Liane Rae | P-Purchase | 1,001 | $49.95 | 2026-09-01 |
| Teplitsky Liane Rae | P-Purchase | 1,024 | $48.80 | 2026-08-31 |
| Teplitsky Liane Rae | P-Purchase | 1,034 | $48.35 | 2026-08-28 |
| Teplitsky Liane Rae | P-Purchase | 1,036 | $48.23 | 2026-08-26 |
| Teplitsky Liane Rae | A-Award | 200,000 | — | 2026-08-08 |